Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Financial Report: Genzyme 1Q | Contract Pharma

What are you searching for?

Sign in
Breaking News, Financial News

Financial Report: Genzyme 1Q

Myozyme sales were flat at $67.4 million. In February, the company received EU approval of Myozyme produced at the 4000 L scale.

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Genzyme 1Q

1Q Revenues: $1.1 billion (+4%)

1Q Earnings: $195.5 million (+35%)

Comments: Myozyme sales were flat at $67.4 million. In February, the company received EU approval of Myozyme produced at the 4000 L scale. Fabrazyme sales were $122.2 million (+5%). Cerezyme sales were $296.0 million (-3%). Sales of Aldurazyme were flat at $36.8 million. Renvela and Renagel sales were $170.6 million (+1). Sales of Thyrogen were up 15% to $38.8 million. Revenue from the company’s Hematologic Oncology segment was $35.9 million (+50%), driven by the launch of Mozobil and an increase in U.S. sales of Clolar.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters